Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2009386 | 0.87 | HTR6 (0.47) | HTR6NPSR1ALDH1A1KMT2AMEN1 | |
| SCHEMBL2007342 | 0.84 | HTR6 (0.50) | HTR6ALDH1A1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL2002360 | 0.84 | SIGMAR1 (0.48) | HTR6ALDH1A1KMT2AMEN1SIGMAR1 | |
| SCHEMBL2006334 | 0.81 | HTR6 (0.44) | HTR6KDM4ESIGMAR1 | |
| SCHEMBL2006686 | 0.81 | HTR2B (0.46) | HTR6NPSR1POLBALDH1A1KDM4E | |
| SCHEMBL2005298 | 0.80 | HTR6 (0.48) | HTR6ALDH1A1KMT2AMEN1SIGMAR1 | |
| SCHEMBL2011983 | 0.77 | HTR2B (0.43) | HTR6ALDH1A1KDM4ERAB9A | |
| SCHEMBL2011056 | 0.77 | ALDH1A1 (0.42) | HTR6ALDH1A1SIGMAR1 | |
| SCHEMBL2007843 | 0.77 | CNR1 (0.47) | HTR6NPSR1ALDH1A1SIGMAR1FAAH | |
| SCHEMBL2007020 | 0.77 | HTR6 (0.44) | HTR6ALDH1A1KMT2AMEN1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | HTR6 2082/4885NPSR1 4230/4885POLB 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.